Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements about fatigue and muscle-related adverse effects are partially supported (fatigue is listed postmarketing; skeletal muscle toxicity is described). However, many assertions about timing, symptom combinations, urgency triggers (e.g., tea/urine, fever), and differential causes (anemia/thyroid/depression/infections/diabetes/typical interactions) are not supported by the provided label excerpts and may be misleading relative to on-label guidance.
Category Scores
Accurate Statements
Lipitor-related fatigue is listed as an adverse reaction associated with LIPITOR therapy (postmarketing experience).
Section 6.2 Postmarketing Experience: includes fatigue.
Atorvastatin (Lipitor) can cause skeletal muscle problems such as myopathy and rare rhabdomyolysis.
Section 5.1 Skeletal Muscle: mentions myopathy and rare rhabdomyolysis with acute renal failure.
Unsupported Statements
Fatigue is a possible side effect of Lipitor.
Label excerpt supports fatigue as a postmarketing adverse reaction, but the statement is framed as general 'possible side effect' without providing the label basis; included here only because the evaluation must match the broader list—however, this statement is actually supported by Section 6.2. (Note: If strict mapping is required, this would be supported; overall scoring still reflects other unsupported items.)
In some people, fatigue from Lipitor can feel persistent.
No 'persistent fatigue' language in provided excerpts.
Lipitor-related fatigue can start after beginning the medicine.
No label excerpt provides timing of onset for fatigue.
Lipitor-related fatigue can start after a dose increase.
No label excerpt links fatigue onset to dose increase timing.
Statins like Lipitor can lead to weakness or ongoing tiredness due to muscle injury (statin-associated muscle symptoms).
Label excerpt describes myopathy/rhabdomyolysis risk but does not define 'statin-associated muscle symptoms' or link fatigue as an 'ongoing tiredness' outcome.
Statin-associated muscle symptoms can include muscle aches, tenderness, or weakness.
Provided excerpts do not list these specific symptom descriptors.
Statin-associated muscle symptoms may be accompanied by fatigue.
No provided label excerpt states fatigue commonly accompanies muscle symptoms.
Fatigue paired with muscle pain or weakness raises the importance of checking with a clinician promptly.
Label excerpt does not provide this specific instruction for fatigue paired with muscle pain/weakness.
Seek urgent medical advice if fatigue comes with severe muscle pain or significant weakness.
No provided label excerpt includes this 'urgent' patient instruction threshold.
Seek urgent medical advice if fatigue comes with dark or tea-colored urine.
No provided label excerpt mentions tea/urine discoloration as an actionable warning for patients.
Seek urgent medical advice if fatigue comes with fever, marked illness, or rapidly worsening symptoms.
No provided label excerpt includes fever/marked illness/rapid worsening as part of a warning instruction.
Persistent fatigue can come from non-Lipitor causes including anemia, thyroid problems, sleep disorders, depression, infections, medication interactions, and uncontrolled diabetes.
Provided label excerpts do not enumerate alternative causes for fatigue.
Doctors may review the full medication list, recent lab work, and symptom timeline to determine whether Lipitor is the likely driver.
No provided label excerpt describes clinician decision-making process for attributing fatigue.
Common next steps include reviewing the dose; checking relevant labs, often including liver enzymes; sometimes performing muscle-related tests; considering a dose reduction; switching to another statin; pausing therapy under medical guidance.
Label excerpts support liver function testing and management (Section 5.2), and temporarily withholding/discontinuing in acute serious myopathy suggestive situations (Section 5.1), but do not support the broad 'common next steps' list (e.g., switching to another statin, performing muscle-related tests, pausing therapy as general guidance for fatigue).
Statin side effects typically emerge after starting the drug or increasing the dose.
No provided label excerpt provides this general timing statement.
The timing of statin side effects can vary by person.
No provided label excerpt supports this general timing variability statement.
The pattern of fatigue onset beginning around the same time as starting Lipitor or changing the dose matters.
No provided label excerpt addresses fatigue onset patterns relative to initiation/titration.
If fatigue is constant and the person is taking Lipitor, they should contact their prescribing clinician to discuss symptoms.
No provided label excerpt gives patient instructions specifically for constant fatigue.
Contacting the prescribing clinician may involve discussing whether labs are needed or whether treatment should be changed.
No provided label excerpt ties clinician action specifically to fatigue.
Contradictions
Low
AI Statement
Do not stop Lipitor on your own unless the clinician advises it.
Label Reference
No contradiction identified. (Included here only if the label excerpt mandates patient to stop; provided excerpts do not do so.)
Important Omissions
The label emphasizes specific monitoring and management: liver function tests prior to and at 12 weeks after initiation and after dose increases, and periodically thereafter; and temporarily withholding/discontinuing when acute, serious conditions suggestive of myopathy occur. The response does not reflect these label-directed monitoring timepoints or criteria beyond generic 'checking labs'.
Importance:
Moderate
The provided label excerpt does not support the included urgency triggers (e.g., tea-colored urine, fever) and dose/treatment change advice specifics; these should be replaced with on-label instructions (e.g., temporary withholding/discontinuation for acute, serious myopathy suggestive conditions; liver test schedule).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes some correct safety concepts (fatigue listed; skeletal muscle toxicity described) but adds many unsupported patient-action triggers and differential cause listings, which could misdirect attention or urgency compared with label-described monitoring/management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Large portion of statements about fatigue timing, symptom descriptors, urgency triggers, and alternative causes are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported adverse reactions (fatigue) and label-described skeletal muscle and liver monitoring/management (Sections 5.1 and 5.2). Remove or qualify unsupported patient instructions (e.g., tea-colored urine, fever thresholds) and avoid broad differential causes not present in the label. Incorporate the label’s liver function test schedule and criteria for dose reduction/withdrawal or temporary withholding/discontinuation in acute, serious myopathy suggestive conditions.